Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Obstructive Sleep Apnea and Overweight/Obesity
NCT07226765Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of maridebart cafraglutide in obstructive sleep apnea (OSA), obesity, sponsored by Amgen. Started Nov 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT07226765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226765.